Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner

Palbociclib, a CDK4/6 inhibitor, has recently been approved for hormone receptor‐positive breast cancer patients. The effects of palbociclib as a treatment for other malignancies, including hepatocellular carcinoma (HCC), are of great clinical interest and are under active investigation. Here, we re...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Oncol
Auteurs principaux: Hsieh, Feng‐Shu, Chen, Yao‐Li, Hung, Man‐Hsin, Chu, Pei‐Yi, Tsai, Ming‐Hsien, Chen, Li‐Ju, Hsiao, Yung‐Jen, Shih, Chih‐Ting, Chang, Mao‐Ju, Chao, Tzu‐I, Shiau, Chung‐Wai, Chen, Kuen‐Feng
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2017
Sujets:
Research Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5537702/
https://ncbi.nlm.nih.gov/pubmed/28453226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12072
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires